Clinical Trials Browser

Completed × dabrafenib × Dermatologic × Clear all

NCT01682083 2026-04-21

COMBI-AD

Phase 3 Completed

870 enrolled 15 charts 1 FDA

Melanoma, Neoplasms

NCT04961619 2025-12-12

LEAD Melanoma

Melanoma

NCT03551626 2025-04-29

COMBI-APlus

Phase 3 Completed

552 enrolled 12 charts

Fever, Melanoma

NCT03944356 2025-03-12

Combi-EU

Melanoma

NCT05260684 2025-03-06

OCEANMIST

716 enrolled 10 charts

Melanoma

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1 Completed

Melanoma

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1/2 Completed

27 enrolled 16 charts

DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT02392871 2024-11-27

CombiRT

Phase 1/2 Completed

Melanoma

NCT03455764 2024-07-31

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

6 enrolled 12 charts

Melanoma

NCT04059224 2023-09-26

TraMel-WT

Phase 2 Completed

Melanoma

NCT04547946 2023-05-30

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Melanoma

NCT05714371 2023-02-06

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2 Completed

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Phase 1 Completed

Melanoma, Neoplasms

NCT01597908 2021-02-24

COMBI-v

Phase 3 Completed

704 enrolled 13 charts

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Melanoma

NCT03352947 2020-12-08

INTERIM

Phase 2 Completed

Melanoma

NCT01682213 2020-05-26

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Phase 2 Completed

23 enrolled 10 charts

Melanoma

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Phase 2 Completed

430 enrolled 61 charts

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 2 Completed

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT02296996 2019-01-23

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Phase 2 Completed

Melanoma

NCT01767454 2017-11-14

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Phase 1 Completed

Melanoma

NCT01954043 2017-11-14

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Phase 1 Completed

Melanoma, Neoplasms

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Phase 3 Completed

251 enrolled 21 charts

Melanoma, Neoplasms

NCT01153763 2017-09-27

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Phase 2 Completed

92 enrolled 22 charts

Melanoma

NCT01928940 2017-07-24

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Phase 2 Completed

12 enrolled 28 charts

Melanoma

NCT02082665 2017-07-24

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Phase 1 Completed

Melanoma, Neoplasms

NCT01619774 2016-12-12

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Phase 2 Completed

28 enrolled 7 charts

Melanoma

NCT01266967 2014-05-08

Break MB

Phase 2 Completed

172 enrolled 23 charts

CNSDermatologic

Brain Neoplasms, Melanoma